Germline loss-of-function mutations in LZTR1 predispo multiple schwannomas

Nature Genetics

46, 182-187

DOI: 10.1038/ng.2855

Citation Report

#	Article	IF	Citations
1	A germline missense mutation in COQ6 is associated with susceptibility to familial schwannomatosis. Genetics in Medicine, 2014, 16, 787-792.	1.1	20
2	Schwannomas and Their Pathogenesis. Brain Pathology, 2014, 24, 205-220.	2.1	151
3	Premature termination of SMARCB1 translation may be followed by reinitiation in schwannomatosis-associated schwannomas, but results in absence of SMARCB1 expression in rhabdoid tumors. Acta Neuropathologica, 2014, 128, 439-448.	3.9	23
4	Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants. Acta Neuropathologica, 2014, 128, 449-452.	3.9	36
5	SMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors. Cancer Genetics, 2014, 207, 373-378.	0.2	71
6	Concurrent DNA Copy-Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients. Human Mutation, 2015, 36, 1088-1099.	1.1	11
7	Neurofibromatosis type 2. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2015, 132, 87-96.	1.0	45
8	Immortalized Human Schwann Cell Lines Derived From Tumors of Schwannomatosis Patients. PLoS ONE, 2015, 10, e0144620.	1.1	10
9	Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology, 2015, 84, 141-147.	1.5	90
10	Synchronous Hodgkinâ€™s lymphoma and schwannomas mimicking refractory Hodgkinâ€™s lymphoma. Annals of Hematology, 2015, 94, 1593-1595.	0.8	0
11	Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms. Seminars in Pediatric Neurology, 2015, 22, 240-258.	1.0	68
12	Is there a link between COQ6 and schwannomatosis?. Genetics in Medicine, 2015, 17, 312-313.	1.1	7
13	Response to Trevisson et al.. Genetics in Medicine, 2015, 17, 313-314.	1.1	1
14	Mosaic Neurocutaneous Disorders and Their Causes. Seminars in Pediatric Neurology, 2015, 22, 207-233.	1.0	81
15	Hereditary Predisposition to Primary CNS Tumors. Molecular Pathology Library, 2015, , 1-22.	0.1	0
16	Cancer genomics: why rare is valuable. Journal of Molecular Medicine, 2015, 93, 369-381.	1.7	8
17	Familial schwannomatosis with a germline mutation of SMARCB1 in Japan. Brain Tumor Pathology, 2015, 32, 216-220.	1.1	11
18	Segmental neurofibromatosis type 2: discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb. BMC Medical Genomics, 2015, 8, 2.	0.7	24

#	Article	IF	Citations
19	Broadening the spectrum of SMARCB1-associated malignant tumors: a case of uterine leiomyosarcoma in a patient with schwannomatosis. Human Pathology, 2015, 46, 1226-1231.	1.1	10
20	Pediatric Peripheral Nerve Tumors. , 2015, , 839-846.		4
21	Expanding schwannomatosis phenotype. Journal of Neuro-Oncology, 2015, 122, 607-609.	1.4	5
22	Rare variants inSOS2andLZTR1are associated with Noonan syndrome. Journal of Medical Genetics, 2015, 52, 413-421.	1.5	187
23	Identification of a novel germline SMARCB1 nonsense mutation in a family manifesting both schwannomatosis and unilateral vestibular schwannoma. Journal of Neuro-Oncology, 2015, 125, 439-441.	1.4	9
25	Expanding the mutational spectrum of LZTR1 in schwannomatosis. European Journal of Human Genetics, 2015, 23, 963-968.	1.4	58
26	ACTA OTORHINOLARYNGOLOGICA ITALICA. Acta Otorhinolaryngologica Italica, 2016, 36, 345-367.	0.7	49
27	Type 1 papillary renal cell carcinoma in a patient with schwannomatosis: Mosaic versus loss of <scp>SMARCB</scp>1 expression in respectively schwannoma and renal tumor cells. Genes Chromosomes and Cancer, 2016, 55, 350-354.	1.5	8
28	Multiparametric wholeâ€body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosis. Journal of Magnetic Resonance Imaging, 2016, 44, 794-803.	1.9	22
29	Molecular Analysis of Hybrid Neurofibroma/Schwannoma Identifies Common Monosomy 22 and Î±-T-Catenin/CTNNA3 as a Novel Candidate Tumor Suppressor. American Journal of Pathology, 2016, 186, 3285-3296.	1.9	22
30	Utility of positron emission tomography in schwannomatosis. Journal of Clinical Neuroscience, 2016, 30, 138-140.	0.8	10
31	Biochemical Insights into Merlin/NF2 Pathophysiology and Biologically Targeted Therapies in Childhood NF2 and Related Forms. Journal of Pediatric Biochemistry, 2016, 05, 120-130.	0.2	0
32	Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation. Child's Nervous System, 2016, 32, 2403-2413.	0.6	9
33	The genomic landscape of schwannoma. Nature Genetics, 2016, 48, 1339-1348.	9.4	124
34	Multifocal nerve lesions and LZTR1 germline mutations in segmental schwannomatosis. Annals of Neurology, 2016, 80, 625-628.	2.8	25
35	Pathogenetics of the RASopathies. Human Molecular Genetics, 2016, 25, R123-R132.	1.4	87
36	All things rhabdoid and SMARC: An enigmatic exploration with Dr. Louis P. Dehner. Seminars in Diagnostic Pathology, 2016, 33, 427-440.	1.0	27
37	Noonan syndrome-causing genes: Molecular update and an assessment of the mutation rate. International Journal of Pediatrics and Adolescent Medicine, 2016, 3, 133-142.	0.5	59

#	Article	IF	Citations
38	Expansion of the RASopathies. Current Genetic Medicine Reports, 2016, 4, 57-64.	1.9	85
39	Chromosome 22q12.1 microdeletions: confirmation of the MN1 gene as a candidate gene for cleft palate. European Journal of Human Genetics, 2016, 24, 51-58.	1.4	10
40	Pediatric schwannomatosis, a rare but distinct form of neurofibromatosis. Pediatric Radiology, 2016, 46, 430-435.	1.1	10
41	Recent developments in brain tumor predisposing syndromes. Acta OncolÃ³gica, 2016, 55, 401-411.	0.8	31
42	Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro-Oncology, 2016, 18, 624-638.	0.6	94
43	Unilateral vestibular schwannoma in a patient with schwannomatosis in the absence of LZTR1 mutation. Journal of Neurosurgery, 2016, 125, 1469-1471.	0.9	10
45	Biomarkers Applied to Specific Tumor Types. , 2016, , 59-98.		0
46	Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution. Journal of Neurosurgery: Spine, 2016, 24, 145-154.	0.9	58
47	Recent advances in RASopathies. Journal of Human Genetics, 2016, 61, 33-39.	1.1	290
48	An unusual case of schwannomatosis with bilateral maxillary sinus schwannomas and a novel SMARCB1 gene mutation. Journal of Neurosurgery: Spine, 2016, 24, 160-166.	0.9	3
49	Neurocutaneous Syndromes and Brain Tumors. Journal of Child Neurology, 2016, 31, 1399-1411.	0.7	15
50	Neurofibromatosis as a gateway to better treatment for a variety of malignancies. Progress in Neurobiology, 2017, 152, 149-165.	2.8	10
51	Childhood cancer predisposition syndromesâ€"A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. American Journal of Medical Genetics, Part A, 2017, 173, 1017-1037.	0.7	200
53	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 2017, 169, 1327-1341.e23.	13.5	1,794
54	Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders. Clinical Cancer Research, 2017, 23, e54-e61.	3.2	76
55	Pediatric Non-vestibular Schwannoma. Pediatric and Developmental Pathology, 2017, 20, 232-239.	0.5	8
56	A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas. Child's Nervous System, 2017, 33, 933-940.	0.6	52
57	A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes. Journal of Genetic Counseling, 2017, 26, 387-434.	0.9	52

#	Article	IF	Citations
58	Constitutional LZTR1 mutation presenting with a unilateral vestibular schwannoma in a teenager. Clinical Genetics, 2017, 92, 540-543.	1.0	9
59	The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis. Human Genetics, 2017, 136, 129-148.	1.8	106
60	Identification of candidate genes for devil facial tumour disease tumourigenesis. Scientific Reports, 2017, 7, 8761.	1.6	20
61	Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development. Nature Communications, 2017, 8, 300.	5.8	70
62	Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1 -related schwannomatosis. Neurology, 2017, 88, 87-92.	1.5	104
63	Orbital peripheral nerve sheath tumors. Survey of Ophthalmology, 2017, 62, 43-57.	1.7	36
66	Neurofibromatosis type 2 French cohort analysis using a comprehensive NF2 molecular diagnostic strategy. Neurochirurgie, 2018, 64, 335-341.	0.6	6
67	Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants. Genetics in Medicine, 2018, 20, 1175-1185.	1.1	133
68	Pain correlates with germline mutation in schwannomatosis. Medicine (United States), 2018, 97, e9717.	0.4	20
69	The Personal Genome Project Canada: findings from whole genome sequences of the inaugural 56 participants. Cmaj, 2018, 190, E126-E136.	0.9	57
70	Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis. Neuro-Oncology, 2018, 20, 917-929.	0.6	48
71	SMARCB1-deficient Tumors of Childhood: A Practical Guide. Pediatric and Developmental Pathology, 2018, 21, 6-28.	0.5	76
72	Neurofibromatosis and Schwannomatosis. Seminars in Neurology, 2018, 38, 073-085.	0.5	53
73	Lymph node metastatic melanoma from ungual melanoma: Identification of somatic mutations in <scp>KIT</scp> and <scp>LZTR</scp>1. Journal of Dermatology, 2018, 45, e5-e6.	0.6	2
74	Familial Tumor Syndromes. , 2018, , 505-545.		5
75	Integration of Cancer Data through Multiple Mixed Graphical Model. , 2018, , .		0
76	Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination. Science, 2018, 362, 1177-1182.	6.0	133
77	LZTR1 is a regulator of RAS ubiquitination and signaling. Science, 2018, 362, 1171-1177.	6.0	142

#	Article	IF	Citations
78	Molecular genetics of 22q11.2 deletion syndrome. American Journal of Medical Genetics, Part A, 2018, 176, 2070-2081.	0.7	96
79	Coâ€œoccurrence of schwannomatosis and rhabdoid tumor predisposition syndrome 1. Molecular Genetics & Genomic Medicine, 2018, 6, 627-637.	0.6	13
80	Benign Intracranial Tumors. Neurologic Clinics, 2018, 36, 501-516.	0.8	11
81	RAS GTPase-dependent pathways in developmental diseases: old guys, new lads, and current challenges. Current Opinion in Cell Biology, 2018, 55, 42-51.	2.6	18
82	Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas. Human Genetics, 2018, 137, 543-552.	1.8	25
83	Genetic Evaluation of Common Neurocutaneous Syndromes. Pediatric Neurology, 2018, 89, 3-10.	1.0	14
84	Neurofibromatosis type 1. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 148, 799-811.	1.0	84
85	Schwannomatosis: a genetic and epidemiological study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1215-1219.	0.9	111
86	Spindle Cell Tumors of Adults. , 2019, , 15-100.		0
87	Applications of Molecular Testing to Differential Diagnosis. , 2019, , 513-556.		0
88	Segmental schwannomatosis: characteristics in 12 patients. Orphanet Journal of Rare Diseases, 2019, 14, 207.	1.2	16
89	Posterior Mediastinal Schwannoma (Neurilemmoma). Mayo Clinic Proceedings, 2019, 94, 559-560.	1.4	2
90	Molecular foundations of primary spinal tumorsâ€”implications for surgical management. Annals of Translational Medicine, 2019, 7, 222-222.	0.7	10
91	The Role of Merlin/NF2 Loss in Meningioma Biology. Cancers, 2019, 11, 1633.	1.7	44
92	In the line-up: deleted genes associated with DiGeorge/22q11.2 deletion syndrome: are they all suspects?. Journal of Neurodevelopmental Disorders, 2019, 11, 7.	1.5	56
93	Neurocutaneous Syndromes. , 2019, , 389-424.		0
94	Coexistence of schwannomatosis and glioblastoma in two families. European Journal of Medical Genetics, 2019, 62, 103680.	0.7	9
95	Genetic Predisposition to Childhood Cancer in the Genomic Era. Annual Review of Genomics and Human Genetics, 2019, 20, 241-263.	2.5	27

#	Article	IF	Citations
96	Further support linking the 22q11.2 microduplication to an increased risk of bladder exstrophy and highlighting LZTR1 as a candidate gene. Molecular Genetics & Genomic Medicine, 2019, 7, e666.	0.6	9
97	Capture and â€œself-releaseâ€•of circulating tumor cells using metalâ€“organic framework materials. Nanoscale, 2019, 11, 8293-8303.	2.8	25
98	RIT1 oncoproteins escape LZTR1-mediated proteolysis. Science, 2019, 363, 1226-1230.	6.0	66
99	Identification of Novel Regulatory Genes in APAP Induced Hepatocyte Toxicity by a Genome-Wide CRISPR-Cas9 Screen. Scientific Reports, 2019, 9, 1396.	1.6	8
102	78 Genetics of Neurofibromatosis Type 2. , 2019, , .		0
103	Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling. Human Molecular Genetics, 2019, 28, 1007-1022.	1.4	58
104	Tumour stem cells in schwannoma: A review. Journal of Clinical Neuroscience, 2019, 62, 21-26.	0.8	13
105	Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1â€“PPP1CB complexes. Human Genetics, 2019, 138, 21-35.	1.8	50
106	Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. Genetics in Medicine, 2019, 21, 1525-1533.	1.1	47
107	Oligo-astrocytoma in LZTR1-related Noonan syndrome. European Journal of Medical Genetics, 2020, 63, 103617.	0.7	17
108	LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases. Cell Death and Differentiation, 2020, 27, 1023-1035.	5.0	70
109	Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups. Haematologica, 2020, 105, 951-960.	1.7	53
110	Curse of the devil: molecular insights into the emergence of transmissible cancers in the Tasmanian devil (Sarcophilus harrisii). Cellular and Molecular Life Sciences, 2020, 77, 2507-2525.	2.4	12
111	Providing more evidence on LZTR1 variants in Noonan syndrome patients. American Journal of Medical Genetics, Part A, 2020, 182, 409-414.	0.7	16
112	LncRNA LL22NC03-N14H11.1 promoted hepatocellular carcinoma progression through activating MAPK pathway to induce mitochondrial fission. Cell Death and Disease, 2020, 11, 832.	2.7	18
113	Therapeutic Development in Neurofibromatosis. , 0, , .		3
114	Whole Genome Sequencing Identifies Key Genes in Spinal Schwannoma. Frontiers in Genetics, 2020, 11, 507816.	1.1	8
115	Surgical Management of Multifocal Trigeminal Schwannomas. Operative Neurosurgery, 2020, 19, 659-666.	0.4	2

#	Article	IF	Citations
116	Identification of Genomic Alterations in Sporadic Pancreatic Neurogenic Tumors. Pancreas, 2020, 49, 1393-1397.	0.5	1
117	Multidisciplinary Approach to Neurofibromatosis Type 1. , 2020, , .		1
118	Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2. Otology and Neurotology, 2020, 41, e529-e537.	0.7	13
119	Neurocutaneous disorders. , 2020, , 1-26.		1
120	Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism. Child's Nervous System, 2020, 36, 2285-2295.	0.6	12
121	Simultaneous Detection of NF1, SPRED1, LZTR1, and NF2 Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients. Genes, 2020, 11, 671.	1.0	5
122	Intronic CRISPR Repair in a Preclinical Model of Noonan Syndromeâ€“Associated Cardiomyopathy. Circulation, 2020, 142, 1059-1076.	1.6	43
123	Analysis of genes within the schizophrenia-linked 22q11.2 deletion identifies interaction of night owl/LZTR1 and NF1 in GABAergic sleep control. PLoS Genetics, 2020, 16, e1008727.	1.5	20
124	Sporadic vestibular schwannoma: a molecular testing summary. Journal of Medical Genetics, 2021, 58, 227-233.	1.5	11
125	Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. Acta Neuropathologica, 2021, 141, 101-116.	3.9	26
126	LZTR1 â€related spinal schwannomatosis and 7q11.23 duplication syndrome: A complex phenotype with dual diagnosis. Molecular Genetics & Genomic Medicine, 2021, 9, e1560.	0.6	2
128	Schwannomatosis: Review of Diagnosis and Management. , 2021, , 371-382.		0
129	Diagnostic Pathology of Tumors of Peripheral Nerve. Neurosurgery, 2021, 88, 443-456.	0.6	43
130	Clinical features of multiple spinal schwannomas without vestibular schwannomas. Journal of Orthopaedic Science, 2022, 27, 563-568.	0.5	4
131	Typical 22q11.2 deletion syndrome appears to confer a reduced risk of schwannoma. Genetics in Medicine, 2021, 23, 1779-1782.	1.1	3
132	Structural Model for Recruitment of RIT1 to the LZTR1 E3 Ligase: Evidences from an Integrated Computational Approach. Journal of Chemical Information and Modeling, 2021, 61, 1875-1888.	2.5	1
133	Enlarged spinal nerve roots in RASopathies: Report of two cases. European Journal of Medical Genetics, 2021, 64, 104187.	0.7	2
134	Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition. Nature Genetics, 2021, 53, 707-718.	9.4	61

#	Article	IF	Citations
135	Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. International Journal of Molecular Sciences, 2021, 22, 5850.	1.8	87
136	In vivo Functional Genomics for Undiagnosed Patients: The Impact of Small GTPases Signaling Dysregulation at Pan-Embryo Developmental Scale. Frontiers in Cell and Developmental Biology, 2021, 9, 642235.	1.8	3
137	Generation of a Mouse Model to Study the Noonan Syndrome Gene Lztr1 in the Telencephalon. Frontiers in Cell and Developmental Biology, 2021, 9, 673995.	1.8	1
138	Skull Base Tumors: Neuropathology and Clinical implications. Neurosurgery, 2021, 90, .	0.6	3
139	Minor Intron Splicing from Basic Science to Disease. International Journal of Molecular Sciences, 2021, 22, 6062.	1.8	13
140	Loss-of-Function Mutations in TRAF7 and KLF4 Cooperatively Activate RAS-Like GTPase Signaling and Promote Meningioma Development. Cancer Research, 2021, 81, 4218-4229.	0.4	13
141	Pathogenic noncoding variants in the neurofibromatosis and schwannomatosis predisposition genes. Human Mutation, 2021, 42, 1187-1207.	1.1	5
142	Spontaneous resolution of nonimmune hydrops fetalis in a fetus with TP63 gene mutation and LZTR1 gene variants. Clinical Case Reports (discontinued), 2021, 9, e04624.	0.2	0
143	The Forgotten Phacomatoses: A Neuroimaging Review of Rare Neurocutaneous Disorders. Current Problems in Diagnostic Radiology, 2022, 51, 747-758.	0.6	3
144	The role of E3 ubiquitin ligases in the development and progression of glioblastoma. Cell Death and Differentiation, 2021, 28, 522-537.	5.0	43
145	Approach to patients with the neoplasms associated with neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. , 2021, , 210-228.		0
146	Pediatric Surgical Pathology of Head and Neck Tumors of the Peripheral Nerve and Paraganglionic System. , 2021, , 489-498.		0
147	Genetics of Nerve Tumors. , 2021, , 17-27.		0
148	Genetic Aspects of Peripheral Nervous System Tumors. , 2021, , 331-345.		0
149	Lung Tumors. , 2017, , 353-575.		1
150	Cullin 3 and Its Role in Tumorigenesis. Advances in Experimental Medicine and Biology, 2020, 1217, 187-210.	0.8	16
151	Neuropathies in the setting of Neurofibromatosis tumor syndromes: Complexities and opportunities. Experimental Neurology, 2018, 299, 334-344.	2.0	22
152	Germline Mutations for Novel Candidate Predisposition Genes in Sporadic Schwannomatosis. Clinical Orthopaedics and Related Research, 2020, 478, 2442-2450.	0.7	3

#	Article	IF	Citations
153	Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling. JCI Insight, 2020, 5, .	2.3	14
154	KIR2DL5 mutation and loss underlies sporadic dermal neurofibroma pathogenesis and growth. Oncotarget, 2017, 8, 47574-47585.	0.8	8
155	Identification of RECK as an evolutionarily conserved tumor suppressor gene for zebrafish malignant peripheral nerve sheath tumors. Oncotarget, 2018, 9, 23494-23504.	0.8	4
156	The Neurofibromatoses. Deutsches Ärzteblatt International, 2020, 117, 354-360.	0.6	32
157	C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis. International Journal of Molecular Sciences, 2020, 21, 3569.	1.8	5
158	Review of the principles of complexity in business administration and application in financial statements. African Journal of Business Management, 2014, 8, 48-54.	0.4	4
160	Schwannomas. Molecular Pathology Library, 2015, , 201-211.	0.1	0
161	Schwannomatosis. , 2016, , 576-577.		0
162	Tumour suppressor/DNA-repair disorders. , 2016, , 193-254.		0
163	Malignant Rhabdoid Tumors and Tumors with Rhabdoid Features. , 2016, , 1-25.		0
164	Malignant Rhabdoid Tumors and Tumors with Rhabdoid Features. , 2017, , 1359-1383.		2
165	Neurofibromatosis 2. , 2017, , 1-32.		0
167	High-Throughput Tabular Data Processor â€“ Platform independent graphical tool for processing large data sets. PLoS ONE, 2018, 13, e0192858.	1.1	1
168	Molecular Studies of Candidate Gene Somatic Mutations in Human Schwannoma Tumors. Journal of Undergraduate Research (Gainesville, Fla), 2019, 20, .	0.0	0
171	Integration of genetic, transcriptomic, and clinical data provides insight into 16p11.2 and 22q11.2 CNV genes. Genome Medicine, 2021, 13, 172.	3.6	16
172	Neurofibromatoses. Hematology/Oncology Clinics of North America, 2022, 36, 253-267.	0.9	8
173	Cauda Canis: Variation of a Tinelâ€™s Sign for a Sciatic Nerve Tumor. Case Reports in Neurological Medicine, 2020, 2020, 1-4.	0.3	1
174	Neurofibromatosis 2. , 2020, , 965-988.		0

#	Article	IF	Citations
175	Neurofibromatosis type 1. , 2020, , 185-200.		1
176	Legius Syndrome, Other CafÃ©-au-lait Diseases and Differential Diagnosis of NF1. , 2020, , 233-247.		0
178	Targeted massively parallel sequencing of candidate regions on chromosome 22q predisposing to multiple schwannomas: an analysis of 51 individuals in a single center experience. Human Mutation, 2021, , .	1.1	3
179	An update on cutaneous tumours with neural differentiation. Diagnostic Histopathology, 2021, , .	0.2	0
180	DGCR8 and the six hit, three-step model of schwannomatosis. Acta Neuropathologica, 2022, 143, 115-117.	3.9	10
181	Genetic architecture of protein expression and its regulation in the mouse brain. BMC Genomics, 2021, 22, 875.	1.2	3
183	How can same-gene mutations promote both cancer and developmental disorders?. Science Advances, 2022, 8, eabm2059.	4.7	29
184	Identification of a Ubiquitin Related Genes Signature for Predicting Prognosis of Prostate Cancer. Frontiers in Genetics, 2021, 12, 778503.	1.1	5
187	Adrenal schwannoma: why should endocrinologists be aware of this uncommon tumour?. Endocrine, 2022, 75, 684-697.	1.1	7
188	Defective protein degradation in genetic disorders. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166366.	1.8	2
189	The RASopathies: from pathogenetics to therapeutics. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	41
190	Neurological features of Noonan syndrome and related <scp>RASopathies</scp> : Pain and nerve enlargement characterized by nerve ultrasound. American Journal of Medical Genetics, Part A, 2022, , .	0.7	3
191	The genetics and diagnosis of pediatric neurocutaneous disorders: Neurofibromatosis and tuberous sclerosis complex. Clinics in Dermatology, 2022, 40, 374-382.	0.8	4
192	ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis. European Journal of Human Genetics, 2022, 30, 812-817.	1.4	11
193	Comparison of the frequency of lossâ€ofâ€function LZTR1 variants between schwannomatosis patients and the general population. Human Mutation, 2022, 43, 919-927.	1.1	2
194	Reâ€evaluation of missense variant classifications in NF2. Human Mutation, 2022, 43, 643-654.	1.1	5
195	Origins of biallelic inactivation of NF2 in neurofibromatosis type 2. Neuro-Oncology, 2022, 24, 903-913.	0.6	4
196	Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor. Experimental Dermatology, 2022, 31, 775-780.	1.4	3

#	Article	IF	Citations
203	A mini review of giant invasive sacral schwannoma. Human Pathology Reports, 2022, 28, 300643.	0.1	0
204	WP1066 induces cell death in a schwannomatosis patientâ€“derived schwannoma cell line. Journal of Physical Education and Sports Management, 2022, 8, a006178.	0.5	2
205	Clinical characteristics and genetic testing outcome of suspected hereditary peripheral nerve sheath tumours in a tertiary cancer institution in Singapore. Hereditary Cancer in Clinical Practice, 2022, 20, .	0.6	1
206	Cardiovascular Abnormalities and Gene Mutations in Children With Noonan Syndrome. Frontiers in Genetics, 0, 13, .	1.1	3
207	Screening of potential novel candidate genes in schwannomatosis patients. Human Mutation, 2022, 43, 1368-1376.	1.1	3
208	Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genetics in Medicine, 2022, 24, 1967-1977.	1.1	60
209	Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis. American Journal of Medical Genetics, Part A, 2022, 188, 2672-2683.	0.7	4
210	Identification of Spliceogenic Variants beyond Canonical GT-AG Splice Sites in Hereditary Cancer Genes. International Journal of Molecular Sciences, 2022, 23, 7446.	1.8	1
211	Bibliometric analysis of the top 100 most-cited articles in neurofibromatosis. , 0, 13, 282.		2
212	LZTR1 molecular genetic overlap with clinical implications for Noonan syndrome and schwannomatosis. BMC Medical Genomics, 2022, 15, .	0.7	5
213	Dysregulated minor intron splicing in cancer. Cancer Science, 2022, 113, 2934-2942.	1.7	7
214	Redefining germline predisposition in children with molecularly characterized ependymoma: a population-based 20-year cohort. Acta Neuropathologica Communications, 2022, 10, .	2.4	9
215	Cancer-associated genodermatoses. Russian Journal of Pediatric Hematology and Oncology, 2022, 9, 60-74.	0.1	0
216	22q11.2 deletion syndrome: Future directions. , 2022, , 406-418.		0
217	Reproduction, prenatal screening, and diagnosis in 22q11.2 deletion syndrome. , 2022, , 370-386.		0
218	Segmental Schwannomatosis of the Lower Extremity â€“ A Case Series. Neurology India, 2022, 70, 2132.	0.2	0
219	A Comprehensive Pan-Cancer Analysis of the Tumorigenic Effect of Leucine-Zipper-Like Transcription Regulator (LZTR1) in Human Cancer. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-19.	1.9	2
220	Hereditary Cancer and Cancer Predisposition Syndromes. Advances in Molecular Pathology, 2022, 5, 9-27.	0.2	0

#	Article	IF	Citations
221	The molecular genetics of <scp>RASopathies</scp>: An update on novel disease genes and new disorders. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2022, 190, 425-439.	0.7	11
222	LZTR1Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL. Cancer Discovery, 2023, 13, 702-723.	7.7	4
223	De novo CLCN3 variants affecting Gly327 cause severe neurodevelopmental syndrome with brain structural abnormalities. Journal of Human Genetics, 0, , .	1.1	1
224	Cancer incidence and surveillance strategies in individuals with <scp>RASopathies</scp>. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 0, , .	0.7	3
225	Lung Tumors. , 2021, , 353-596.		0
226	Copy Number Variations in Children with Tourette Syndrome: Systematic Investigation in a Clinical Setting. Genes, 2023, 14, 500.	1.0	2
227	miRNA biogenesis and inherited disorders: clinico-molecular insights. Trends in Genetics, 2023, 39, 401-414.	2.9	13
234	Nerve sheath tumors. , 2016, , 637-693.		0
235	Somatic mosaic SOX10 indel mutations underlie a form of segmental schwannomatosis. Acta Neuropathologica, 0, , .	3.9	0